2026-2027 COVID-19 Vaccination
October 26, 2026 (Issue: 1766)
The FDA has licensed 2026-2027 formulas of the mRNA
COVID-19 vaccines Comirnaty, Spikevax, and mNEXSPIKE
and the adjuvanted protein subunit COVID-19 vaccine
Nuvaxovid.
- COVID-19 update: mNexspike – a new Moderna mRNA vaccine for COVID-19. Med Lett Drugs Ther 2025; 67:119.
- CDC. Variants and genomic surveillance. August 28, 2025. Available at: https://bit.ly/4B7NzYX. Accessed: October 7, 2026.
- CDC. COVID-19 vaccination guidance for people who are immunocompromised. September 23, 2026. Available at: https://bit.ly/4rqKz56. Accessed: October 7, 2026.
- Infectious Diseases Society of America. IDSA 2026 guidelines on the use of vaccines for the prevention of seasonal COVID-19, influenza, and RSV infections in immunocompromised patients. September 2, 2026. Available at https://bit.ly/4roGvCu. Accessed: October 7, 2026.
- CDC. Interim clinical considerations for use of COVID-19 vaccines in the United States. September 23, 2026. Available at: https://bit.ly/3VKN7PQ. Accessed October 7, 2026.
- American College of Obstetricians and Gynecologists. Practice advisory: COVID-19 vaccination considerations for obstetric-gynecologic care. August 2026. Available at: https://bit. ly/4rK7bhd. Accessed: October 7, 2026.
- American Academy of Family Physicians. 2026-2027 influenza, RSV and SARS-CoV-2 immunization recommendations for non-pregnant immunocompetent adults and health care personnel. Available at: https://bit.ly/46CjJ0w. Accessed: October 7, 2026.
- American Academy of Pediatrics. Committee on Infectious Diseases. Recommendations for COVID-19 vaccines in infants, children, and adolescents, 2026-2027: policy statement. Pediatrics 2026 September 2 (epub).
- RA Lipson et al. COVID-19 vaccine effectiveness and safety for the 2026-2027 respiratory season. JAMA 2026 September 2 (epub). doi:10.1001/jama.2026.18191
- N Vicic et al. Interim effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 vaccines against COVID-19-related outcomes among adults aged ≥65 years in the United States. Infect Dis Ther 2026; 15:2307. doi:10.1007/s40121-026-01395-4
- HJ Appaneal et al. BNT162b2 LP.8.1 early vaccine effectiveness against COVID-19 emergency department, urgent care, and outpatient visits. Nat Commun 2026; 17:6912. doi:10.1038/s41467-026-73798-3
- RE Wiegand et al. Interim estimated effectiveness of 2025-2026 COVID-19 vaccines in adults using a test-negative design. JAMA Netw Open 2026; 9:e2625152. doi:10.1001/jamanetworkopen.2026.25152
- COVID-19 update: mRNA COVID-19 vaccines and myocarditis. Med Lett Drugs Ther 2025; 67:119.
- EA Toraih et al. Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals. Vaccine 2026; 91:129001. doi:10.1016/j.vaccine.2026.129001
- D Kilday et al. Association between COVID-19 by variant period and delivery-related outcomes in the United States. PLoS One 2026; 21:e0355223. doi:10.1371/journal.pone.0355223
- LH Zauche et al. Neonatal and infant health outcomes following maternal COVID-19 vaccination: CDC’s COVID-19 vaccine pregnancy registry. J Pediatr Health Care 2026 July 22 (epub). doi:10.1016/j.pedhc.2026.06.017
- SA Madni et al. Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry. Vaccine 2026; 79:128461. doi:10.1016/j.vaccine.2026.128461
- AA Ciesla et al. Effectiveness of 2023-2024 coronavirus disease 2019 (COVID-19) vaccines in pregnant women. Obstet Gynecol 2026; 147:569. doi:10.1097/aog.0000000000006145
- E McClymont et al. The role of vaccination in maternal and perinatal outcomes associated with COVID-19 in pregnancy. JAMA 2026; 335:154. doi:10.1001/jama.2025.21001
- HN Eide et al. COVID-19 mRNA vaccination in pregnancy and risk of infection in early childhood. Pediatrics 2026 March 20 (epub). doi:10.1542/peds.2025-073661
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
